CN1781497A - Plant female sex hormone and probiotics for keeping woman health - Google Patents
Plant female sex hormone and probiotics for keeping woman health Download PDFInfo
- Publication number
- CN1781497A CN1781497A CNA2004100104346A CN200410010434A CN1781497A CN 1781497 A CN1781497 A CN 1781497A CN A2004100104346 A CNA2004100104346 A CN A2004100104346A CN 200410010434 A CN200410010434 A CN 200410010434A CN 1781497 A CN1781497 A CN 1781497A
- Authority
- CN
- China
- Prior art keywords
- compositions
- menopause
- lactobacillus
- dosage form
- spore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The composition for remitting and/or preventing functional disorder of women in premenopause, menopause and postmenopause contains soybean isoflavone and active lactobacillus and preferably lactobacillus spore. The composition is provided in preparation form suitable for oral taking. Preferably, the composition contains also dry horsetail extract, pharmaceutically acceptable calcium salt and/or vitamin D3.
Description
Technical field
The present invention relates to new compositions, said composition can tablet, capsule or is mixed with the powder type oral administration of suspension temporarily, and it is used to promote the health of physiological function and the climacteric and the menopausal women of skeleton.
Background technology
The postmenopausal osteoporosis that causes owing to the ovarian hormone hyposecretion is the modal reason of women's bone-loss.This disorder promptly, obtains prevention by suitable Hormone Replacement Therapy (HRT) by using external source estrogen.Be used for this purpose synthetic estrogens hormone strong drug action and, if incorrect use may cause side effect, particularly during long term administration.
The fracture incidence rate by due to the osteoporosis of Asian countries will be lower than western countries.This species diversity is because at Asian countries's soy food product quilt extensively edible [1] and particularly because the effect of some isoflavone that exists in the Semen sojae atricolor.In fact, soybean isoflavone (SIs) is proved to be [2,3,4,5] and be confirmed [6] to the effect that postmenopausal women's skeleton has Nutrition in the research to OO rat in some clinical researches.
Semen sojae atricolor mainly contains two kinds of isoflavone, i.e. genistin and daidzin.Genistin (MW 432.22) is the β-glucoside of genistin former (MW 270.24).Daidzin (MW 416.23) is the β-glucoside of daidzein (daidzin) (MW 254.24).Genistin and daidzin are relatively large molecules; Their good water solubility, polarity is big.These character have hindered their gastrointestinal absorption and the bioavailability of estrogen part.
But in order to be absorbed and to become biological utilisation, SIs must be hydrolyzed into aglycone, just separates [7] with the glucoside component.This can be that the effect of glycosidase is finished by specific enzymes.Yet human and many mammiferous gastrointestinal tract are not secreted glycosidase, so the isoflavone biology that can not be hydrolyzed and then become can utilize.On the contrary, the certain micro-organisms of intestinal microbial population, particularly some lactobacillus can produce said hydrolyzed and react necessary glycosidase, and this glycosidase is essential [8,9] to the absorption of SIs.Therefore the existence that produces the antibacterial of glycosidase in the gastrointestinal tract is the prerequisite that SIs absorbs and brings into play effect.
Intestinal microbial population altering a great deal between individuality, even in identical subject, the function of intestinal microbial population be also along with food, weather, Drug therapy, disease, or the like difference and change.Thereby, in a lot of experimenters, the glycosidase that produces by intestinal microbial population may be seldom or even do not have, thereby the absorption that jeopardizes SIs.
The purpose of this invention is to provide Orally-administrable, particularly as the compositions of food additive, before being used to alleviate, eliminate and/or preventing puzzlement menopause, in disorder after climacteric of menopause and postmenopausal women and the menopause, comprise the metabolic disturbance of bone, its bone-loss and osseous tissue that can cause increasing risk of bone fracture changes.
The present invention's general introduction
The invention provides and be used to alleviate and prevent compositions in disorder after climacteric and the menopause, it comprises the soybean isoflavone and the Lactobacillus of effective dose, and said composition provides to be applicable to oral dosage form.
Compositions of the present invention comprises soybean isoflavone with estrogen activity and can produce the lactobacillus of glycosidase in intestinal, its objective is that the isoflavone glucoside that will absorb is cracked into the SIs of can absorbed aglycone and guaranteeing to be taken in all intraindividual bioavailability.
The purposes that the present invention also provides said composition to be used to prepare medicine or food additive by the above-mentioned composition of oral effective dose in the individuality of needs, is used for eliminating and prevention climacteric and disorder in menopause.
In principle, the lactobacillus of any type all is suitable for compositions of the present invention.In fact, lactobacillus is the probiotic bacteria with many benefits, and reason is:
● lactobacillus can produce lactic acid, its acidificable intestinal contents, and for disadvantageous condition has been created in the growth of many pathogenic microorganism (escherichia coli, candidiasis etc.), and, on the contrary, for advantageous conditions has been created in the absorption of calcium, ferrum, phosphorus and other nutrients.
● by these mechanism, and by because the pH that the generation of lactic acid causes reduces, lactobacillus improves and balanced intestinal microbial population.This is very useful, particularly when the intestinal microbial population that causes owing to incorrect diet, medicine (particularly antibiotic), weather stress, digestive disorders or malnutrition is not enough or unbalance.In fact, preponderate than fermentative microflora and produce toxin owing to corrupt flora, these situations can cause diarrhoea, constipation, flatulence, dyspepsia, weak and uncomfortable.
● lactobacillus produces protease and lipase, and it is finished the digestion of protein and fat and cuts down these nutrient substance of intestinal microbial population microorganism, and they can produce noxious substance, for example at material that anaerobic decay process produced.
● lactobacillus can produce vitamin K, and it is the necessary factor of blood coagulation; And can produce the several vitamins of B family, it is essential to keeping active metabolism.
● also because lactobacillus can produce special antibiotic substance bacteriocin, it can stop the growth of " being harmful to " flora.Therefore they can eliminate the undesirable microorganism effect of intestinal.
● in addition, lactobacillus is grown on intestinal wall and is bred, thereby form one deck barrier of resisting pathogenic microorganism, these pathogenic microorganism are for example Candida albicans, Salmonelleae, Eschericheae, staphylococcus, clostridium, or the like, it can produce toxin and can cause intestinal infection.
● last, lactobacillus can activate the gastrointestinal immune defence, and it helps to make our body to resist infection and poisonous substance allergy.
In order to realize purpose of the present invention, preferred especially lactobacillus spore (solidifying bacillus cereus), hereinafter be abbreviated as Ls, randomly combine with other lactobacilluss, because the spore of Ls is stable under the general environment condition, need in refrigerator, preserve and can in the cholic secretions of harmonization of the stomach that can kill most of other lactobacilluss, keep active.
It is to be noted that especially Ls produces L-lactic acid by the homofermentation reaction.L-lactic acid, the isomer that just enters the lactic acid in our metabolic pathway is not because of it causes that the whole body acidosis is recommended by World Health Organization (WHO).
In order to produce lactic acid, Ls utilizes the fragment of indigested sugar, cuts down these substrates of harmful kind in the intestinal flora, thereby has suppressed their growth but also help to keep fit.
Because these above-mentioned reasons, lactobacillus, particularly Ls are very useful probiotics, and they also provide many benefits to keeping fit except the bioavailability that can improve SIs.
The further reinforcement of skeleton can realize the useful material of skeleton and joint by adding other.One of them is exactly Herba Equiseti Hiemalis (Herba Equiseti Arvinsis), and it can provide the organic salt of single silicic acid, and it is the solubility body of silicon, in the easy absorption of gastrointestinal tract and therefore easily by biological utilisation.Silicon, with phosphorus, fluoride, magnesium and boron, in the deposition process on the collagen fibril (just the bone mineral composition is accumulated on the organ structure) relation is arranged with hydroxyapatite crystal, the Herba Equiseti Hiemalis is also contained equisetonine, it is the material with gentle diuresis, can be used for adjusting water retention, this situation often took place and causes lower extremity swelling and distension and weight increase in menopause.Also should replenish calcium (use with the absorption that promotes calcium and on skeleton, deposit) in addition, because the demand to calcium always increases during menopause with vitamin D.
Experiment
The purpose of experimental section is the effect of investigation different components in the bone-loss of the ovariectomized rat of prevention, and ovariectomized rat is the postmenopausal osteoporosis model [6] of extensive use.
In brief, exactly under the situation of carrying out the anesthesia of equitesin (equitesin is the mixture of pentobarbital, ethanol, chloral hydrate, propylene glycol, magnesium sulfate solution) peritoneum with the amount of 3ml/kg body weight, excise the ovary of the Sprague-Dawley rat in 95 day age.One group of per 8 rat, being divided into is 4 groups.8 rats of the 5th group carry out sham-operation and the not ovariectomized matched group of conduct.Rat can freely drink water and arbitrarily feeding at interpolation calcium carbonate (0.1g/kg food) and the vitamin D of rodent
3The Harlan food of (1 μ g/kg food).SIs and Ls are suspended in 0.5% the hydroxypropyl emthylcellulose aqueous solution (carrier hereinafter referred to as), and every day is with the stomach tube administration of the dosage of 10ml/kg body weight then.
Each group is carried out following processing.
Organize 1. sham-operations, not ovariectomized matched group: carrier
Organize 2. ovariectomized matched groups: carrier
Organize 3. ovariectomized SIs processed group: genistin 0.5mg/kg body weight+daidzin 0.5mg/kg body weight
Organize 4. ovariectomized SIs+Ls processed group: the Ls spore of genistin 0.5mg/kg body weight+daidzin 0.5mg/kg body weight+800 ten thousand/every kg body weight
Organize 5. ovariectomized SIs+Ls+ Herba Equiseti Hiemalis processed group: Herba Equiseti Hiemalis's stem dry extract of the Ls spore+1.5mg/kg body weight of genistin 0.5mg/kg body weight+daidzin 0.5mg/kg body weight+800 ten thousand/every kg body weight (is standard to contain 7% silicon)
The common suggestion consumption of dosage so that the mankind are used adjusted according to used rat body weight in the research.
Soybean isoflavone: common daily dose is 20-80mg, preferred 40-60mg.
The lactobacillus spore: common daily dose is 0.75 hundred million-1,500,000,000 spore, hundred million of preferred 2.5-10.
The Herba Equiseti Hiemalis: common daily dose is for being equivalent to 3-10mg silicon dioxide.
Calcium: the daily dietary allowance (RDDA) that the adult women recommends is 800mg.For the present invention, the daily dose of preferred 100mg to 300mg is with its replenishing as the calcium that is comprised in diet.
Vitamin D
3: adult women's RDDA is 5 μ g.For compositions of the present invention, the daily dose of preferred 3-5 μ g.
In six weeks after the oophorectomize, put to death with cervical dislocation behind the rat etherization.Take out the rapid weighing in uterus, femur is taken out from soft tissue, and, use Archimedes principle measurement volumes and density, then at 640 ℃ of following ashing 24h with its length of kind of calliper.Each ash samples weighing is dissolved among the HCl of 6N then.In final solution, measure calcium, measure phosphorus by colorimetric analysis by atomic absorption spectrography (AAS).
Calculate the average and standard error of Different Results, and then by the significant difference between each numerical value of t-check estimation.
This research obtains at last the results are shown in Table 1 and can be summarized as follows.
1. with respect to sham-operation animal groups (group 1), the body weight in any oophorectomize animal groups six weeks after spay changes without any significance.
2. on the contrary, in oophorectomize matched group (group 2), uterus weight has the decline of highly significant and femur to descend clearly aspect the content of length, density, ash weight, calcium and phosphorus, thereby shows that estrogen deficiency has negative effect to the nutrition of bone.
3. give the influence of SIs (group 3) to body weight and uterus (with respect to organizing 2) not remarkable (the α estrogen receptor is had no stimulation), but can significantly increase the phosphorus in femur length and the skeleton, thereby show that the nutrition to bone has suitable positive role.
4. add (group 4) among the Ls to SIs and improved the nutriture of bone significantly and surprisingly, shown in the remarkable increase of the sign (content of femur length, density, ash weight, calcium and phosphorus) by all osteotrophy situations, thereby supported the theory of the combination of SIs-Ls, i.e. combination by SIs-Ls has improved the bioavailability of SIs and then has promoted the positive effect of SIs to skeleton.
5. the extra Herba Equiseti Hiemalis extract that adds (group 5) makes all osteotrophy condition flag (content of femur length, density, ash weight, calcium and phosphorus) that unexpected further raising arranged, thereby has confirmed that this natural herb plant product is to the anabolic effect of bone.
In a word, because the raising that the bioavailability of the SIs due to the beneficial natural disposition energy of Ls and enteral calcium and phosphorus absorb, Ls has significantly strengthened SIs to the anabolic effect of bone.The interpolation of Herba Equiseti Hiemalis extract then has further facilitation to the bone anabolism.It should be noted that no matter be that SIs or SIs+Ls all obviously do not influence the weight in uterus, thereby show that it does not have stimulation to the d estrogen receptor.The effect that this and estrogens hormone are produced has formed striking contrast, because the estrogens hormone is to the stimulation of d estrogen receptor, thereby it may produce illeffects in some patients when promoting osteotrophy, and is particularly all the more so under the situation of life-time service.
Therefore, this theory has been supported in this research, the combination that is SIs+Ls is the natural and well-tolerated therapeutic agent that prevents the rat bone-loss, wherein the bone-loss of rat is that this situation also is present in the middle of the postmenopausal women because the estrogens hormonoprivia due to the oophorectomize is caused.Add Herba Equiseti Hiemalis extract and can strengthen the effect that the SIs+Ls combination prevents bone-loss.
On the same group result not after the table 1.6 week treatment.Meansigma methods and standard error
The quantity of body weight and uterus data=8; Femur data bulk=16
Percent change data have also been write down with respect to the oophorectomize matched group of group 2.Significant difference (P
t＜0.05) represents with italic.
| Group | 1 | 2 | 3 | 4 | 5 |
| Body weight g uterus mg femur length mm density g/cm3Ash weight g/cm 3Calcium mmole/cm 3Phosphorus mmole/cm 3? | False control group 262 ± 6 186 ± 11 34.2 ± 02 1045 ± 13 665 ± 0.07 7.02 ± 0.1 3.80 ± 0.03 | Oophorectomize group 260 ± 5 a? 50±4 c? ? 33.3±0.2 d? 958±12 c? 579±6 c? 6.35±0.06 c? 3.46±0.02 c? ? | SIs group 264 ± 7 b +2％ 48±6 b -4％ ? 34.8±0.3 e +4.5％ ％5±11 b +1％ 595±7 b +3％ 6.54±0.10 b +3％ 3.55±0.03 g? +3％ | SIs+Ls group 266 ± 6 b +2％ 57±5 b +14％ ? 35.0±0.2 e +5％ 988±9 f +3％ 605±9 g +4％ 6.75±0.11 e +6％ 3.66±0.03 e? +6％ | SIs+Ls+Equ group 263 ± 8 b +1％ 53±4 b +6％ ? 35.4±0.3 e +6％ 999±10 g +4％ 615±7 e +6％ 688±0.14 e +8％ 3.70±0.03 e? +7％ |
aP
tNS vs. group 1
bP
tNS vs. group 2
cP
t＜0.001 vs. group 1
dP
t＜0.05 vs. group 1
eP
t＜0.001 vs. group 2
fP
t=0.05 vs. group 2
gP
t＜0.05 vs. group 2
The present invention describes in detail
The following example has been described the possible practical application of the present invention but scope of the present invention has not been defined in these embodiment
Embodiment 1: be used for oral tablet
Following prescription has considered to can be used under the condition of the present invention prepare the active ingredient and the excipient (with their technical functionality) of oral system.
Comprise a daily dose in a slice.The technology general knowledge common according to this area prepares tablet, without any need for special or special steps.Following preparation steps is essential in a word:
● weigh up single component;
● prepare press sheet mixture by in suitable dried powder blender, mixing the prescription component;
● the mixture of compacting gained in suitable automatic tableting press, the sheet that obtains having required form and size.
Required component is listed in the table below.
| Active ingredient | Consumption/sheet |
| Calcium carbonate ( *) be equivalent to the calcium vitamin D 3500,000IU/g is equivalent to vitamin D 3Soybean isoflavone 40% dry extract is equivalent to isoflavone Herba Equiseti Arvinsis 7% dry extract and is equivalent to SiO 215,000,000,000/g of lactobacillus spore be equivalent to the spore dicalcium phosphate dihydrate ( **) be equivalent to calcium | 500,000,000 87mg 20mg of 335mg 121mg 0.4mg 5 μ g 150mg 60mg 100mg 7mg 34mg |
(
*) contain 36%m/m calcium
(
*) also be used as excipient
| Excipient | Consumption/sheet | Function |
| Dicalcium phosphate dihydrate hydroxypropyl cellulose microcrystalline Cellulose Pulvis Talci silicon dioxide magnesium stearate | 87.0mg 40.0mg 16.6mg 16.0mg 7.0mg 14.0mg | Fluidizer/anticaking agent binding agent diluent/disintegrating agent fluidizer adsorbent/anti-caking agent lubricant |
Embodiment 2: be used for oral capsule
Following prescription has considered to can be used under the condition of the present invention prepare the active ingredient and the excipient (with their technical functionality) of oral capsule.
Two capsules contain a daily dose.The technology general knowledge common according to this area prepares capsule, without any need for special or special steps.Following preparation steps is essential in a word:
● weigh up single component;
● preparation is used for the mixture of filled capsules in the blender that is suitable for carrying out the dry mixed operation;
● select the hard gelatin capsule of suitable dimension and expection color for use, carrying out the capsule filling in the envelope capsule machine automatically.
Required component is listed in the table below.
| Active ingredient | Consumption/sheet |
| Calcium carbonate ( *) be equivalent to the calcium vitamin D 3500,000IU/g is equivalent to vitamin D 3Soybean isoflavone 40% dry extract is equivalent to isoflavone Herba Equiseti Arvinsis 7% dry extract and is equivalent to SiO 215,000,000,000/g of lactobacillus spore is equivalent to spore | 176.2mg 2.5 hundred million of 60.5mg 0.2mg 2.5 μ g 75mg 30mg 50mg 3.5mg 17mg |
(
*) contain 36%m/m calcium
| Excipient | Consumption/sheet | Function |
| Starch microcrystalline Cellulose magnesium stearate talc | 60.0mg 29.0mg 5.0mg 2.6mg | Diluent/disintegrating agent diluent lubricants glidants |
Embodiment 3: the medicine bag (this powder can be mixed with oral administration mixed suspension temporarily) that comprises powder
Following prescription has considered to can be used to prepare under the condition of the present invention the active ingredient and the excipient (with their technical functionality) of the powder that is fit to make oral administration mixed suspension.
A powder comprises a daily dose.This part powder packets is contained in the medicine bag, and this medicine bag is made up of outside ply of paper, aluminum middle layer and inner polyethylene layer.The technology general knowledge common according to this area prepares medicine bag, without any need for special or special steps.In a word, following preparation steps is essential:
● weigh up single component;
● homogenize mixed composition in the blender that is suitable for carrying out the dry mixed operation;
● hot forming prepares medicine bag on suitable automatic assembly line, and this automatic assembly line wherein also comprises fills and locking device;
● fill on above-mentioned automatic assembly line and the sealing medicine bag, obtain the medicine bag of desired size and shape, this medicine bag contains can be for the interim unit-dose powder of using.
Required component is listed in the table below.
| Active ingredient | Consumption/sheet |
| Calcium carbonate (*) is equivalent to the calcium vitamin D 3500,000IU/g is equivalent to vitamin D 3Soybean isoflavone 40% dry extract is equivalent to isoflavone Herba Equiseti Arvinsis 7% dry extract and is equivalent to SiO 215,000,000,000/g of lactobacillus spore is equivalent to spore | 500,000,000 of 335mg 121mg 0.4mg 5 μ g 150mg 60mg 100mg 7mg 34mg |
(
*) contain 36%m/m calcium
| Excipient | Consumption/sheet | Function |
| Sorbitol citric acid Macrogol 4000 other ( *) | 60.0mg 25.0mg 10mg is an amount of | Diluent/sweetener flavour enhancer lubricant/plasticizer sweetener and flavoring agent |
(
*) sweetener and flavoring agent can arbitrarily add, become according to hobby.
List of references
[1]Ho?SC.Body?measurements，bone?mass?and?frac?tures-does?the?East?differfrom?the?West？Clin?Orthp?Rel?Res?1996；323：75-80
[2]Alekel?DL，Germain?AS，Peterson?CT，Hanson?K?B，Stewart?JW，Toda?T.Isoflavone-rich?soy?protein?isolate?attenuates?bone?loss?in?the?lumbar?spine?ofperimenopausal?women.Am?J?Clin?Nutr?2000；72：844-852
[3]Mei?J，Yeung?SS，Kung?AW，High?dietary?phytoo?estrogen?intake?isassociated?with?higher?bome?mineral?density?in?postmenopausal?but?not?pre-menopausal?women.J?Clin?Endocrinol?Metab?2001；86：5217-5221
[4]Potter?SM，Baum?JA，Teng?H，Stillman?RJ，Shay?NF，Erdman?JW?Jr，Soyprotein?and?isoflavones：their?effects?on?blood?lipids?and?bone?density?inpostmenopausal?women.Am?J?Clin?Nutr?1998；68(suppl)：1377S-1379S
[5]Scheiber?MD，Liu?JH，Subbiah?MT，Rebar?RW，Secchell?KD.Dietaryinclusion?of?whole?soy?foods?results?in?significant?reductions?in?clinical?risk?ractors?forosterporosis?and?cardiovascilar?disease?in?normal?postmenopausal?wanen.Menopause2001；8：384-392
[6]Draper?CR，Edel?MJ，Dick?IM，Randall?AG，Mar?tin?GB，Prince?RL.Phytooertogens?reduce?bone?loss?and?bone?resorption?in?ophorectomised?rarts.J?Nutr1997；127：1795-1799
[7]Izumi?T，Pistula?MK，Osawa?S，Obata?A，Tobe?K，Saito?M，Kataoka?S，Kubota?Y，Kikuchi?M.Soy?Isoflavones?Aglycones?are?adsorbed?faster?and?in?higheramounts?than?their?glucosides?in?humans.J?Nutr?2000；130：1695-1699
[8]Boriello?SP，Setchell?KDR，Axelson?M，Lawson?A?M.Production?andmetabolism?of?lignans?by?the?human?faecal?flora.JAppl?Bacteriol?1985；58：37-43
[9]Setchell?KDR，Boriello?SP，Hulme?P，Kirk?DN，Axelson?M.Non-steroidalestrogens?of?dietary?origin：possible?roles?in?hormone-dependent?diseases.Am?J?ClinNutr?1984；40：569-578.
Claims (10)
1. before being used to alleviate and/or preventing puzzlement menopause, menopause and postmenopausal women's the climacteric and the compositions of disorder in menopause, it is characterized in that said composition contains soybean isoflavone and can promote the Lactobacillus that soybean isoflavone absorbs, said composition provides with the dosage form of oral administration.
2. according to the compositions of claim 1, wherein said lactobacillus comprises lactobacillus spore (solidifying bacillus cereus).
3. according to the compositions of claim 1 or 2, wherein also contain the Herba Equiseti Arvinsis dry extract.
4. the compositions arbitrary according to claim 1 to 3, wherein said dosage form is suitable for soybean isoflavone with 20-80mg, the daily dose administration of preferred 40-60mg.
5. the compositions arbitrary according to claim 1 to 4, wherein said dosage form are suitable for said lactobacillus with 0.75 hundred million-1,500,000,000 spore, the daily dose administration of preferred hundred million spores of 2.5-10.
6. according to the compositions of claim 3, wherein said dosage form is suitable for the daily dose administration of Herba Equiseti Arvinsis dry extract with 3.0-10.0mg and preferred 5-7mg, and this dosage is expressed with the silicon dioxide that contains in the described dry extract.
7. the compositions arbitrary according to claim 1 to 6 wherein also comprises pharmaceutically acceptable calcium salt and/or vitamin D
3
8. the compositions arbitrary according to claim 1 to 7, wherein said dosage form are selected from sheet, capsule or comprise the medicine bag that can temporarily be mixed with the powder of suspension.
9. each compositions of claim 1 to 8 is used to prepare the purposes of medicine or food additive, this medicine or food additive can be for oral use before treatment puzzlement menopause, menopause and postmenopausal women's climacteric and disorder in menopause.
10. according to the purposes of claim 9, it is used to prevent run off with menopause or the insufficient relevant bone of other forms of ovary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100104346A CN1781497A (en) | 2004-11-29 | 2004-11-29 | Plant female sex hormone and probiotics for keeping woman health |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2004100104346A CN1781497A (en) | 2004-11-29 | 2004-11-29 | Plant female sex hormone and probiotics for keeping woman health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1781497A true CN1781497A (en) | 2006-06-07 |
Family
ID=36772371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100104346A Pending CN1781497A (en) | 2004-11-29 | 2004-11-29 | Plant female sex hormone and probiotics for keeping woman health |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1781497A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3116719A1 (en) * | 2020-11-27 | 2022-06-03 | Qufu Normal University | Silicon-Based Food Supplement and Process for Its Preparation |
-
2004
- 2004-11-29 CN CNA2004100104346A patent/CN1781497A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3116719A1 (en) * | 2020-11-27 | 2022-06-03 | Qufu Normal University | Silicon-Based Food Supplement and Process for Its Preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1481676B1 (en) | Phytoestrogens and probiotic for women's health | |
| CN101584747B (en) | Antibacterial antivirus Chinese medicinal composition for animal | |
| TWI580361B (en) | Methods for reducing ruminant methanogenesis | |
| CN103083650A (en) | Composition with bone mineral density addition function, and preparation method as well as application of composition | |
| JP4580034B2 (en) | Calcium ion sustained release agent | |
| CN108541953A (en) | It is a kind of that there is the composition for adjusting enteric microorganism structure and being proliferated thermophilic mucin Ah Kaman Salmonella | |
| CN105287790A (en) | Paederia scandens extract and applications thereof | |
| JP2002234844A (en) | Bone density improver and utilization thereof | |
| CN1785427A (en) | Compound calcium preparation for astronaut | |
| JPH1036256A (en) | Anti-osteoporosis composition | |
| CN1781497A (en) | Plant female sex hormone and probiotics for keeping woman health | |
| TW201336506A (en) | Bone-fortifying agent | |
| CN1262281C (en) | Drugs, foods, drinks and feeds containing cocoa component | |
| CN111494402B (en) | Compound vitamin tablet for livestock and preparation method thereof | |
| CN101450074B (en) | Composition capable of greatly improving gastrointestinal tract function and preventing and treating astriction | |
| JP2008169168A (en) | Bone density increasing agent | |
| CN102247390B (en) | Medicine for treating bacterial air sacculitis in livestock and preparation method thereof | |
| CN102626420B (en) | Mixed preparation containing strontium, calcium and vitamin D | |
| CN1714809A (en) | Drugs, foods, drinks and feeds containing cocoa component | |
| CN111012900B (en) | Composition with bone mineral density increasing function and preparation method and application thereof | |
| JP2004123671A (en) | Nutrient agent and digestive tract agent | |
| CN104546894B (en) | Application of the inulin in the property hyperoxaluria of intestines source | |
| CN106578611A (en) | Specific feed for young ostriches and preparation method thereof | |
| US20170014443A1 (en) | Compositions and methods for treating gastrointestinal disorders for humans and animal husbandry | |
| CN1475227A (en) | Composition for preventing and treating climacteric sgndrome, osteoporosis and mastocancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |